Josep Tabernero
Overview
Explore the profile of Josep Tabernero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
531
Citations
41923
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Luke J, Gelmon K, Siu L, Moreno V, Desai J, Gomez-Roca C, et al.
Clin Cancer Res
. 2024 Dec;
PMID: 39670852
Purpose: To evaluate linrodostat mesylate, a selective, oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, combined with nivolumab ± ipilimumab in advanced solid tumors and hematologic malignancies. Patients And Methods: In this...
12.
Dasari A, Lonardi S, MacLeod B, McPeak S, Tabernero J, Eng C
Future Oncol
. 2024 Nov;
21(3):281-292.
PMID: 39614128
No abstract available.
13.
Mirallas O, Martin-Cullell B, Navarro V, Vega K, Recuero-Borau J, Gomez-Puerto D, et al.
Lancet Reg Health Eur
. 2024 Nov;
46:101063.
PMID: 39529819
Background: Prognostic factors for ambulatory oncology patients have been described, including Eastern Cooperative Oncology Group (ECOG), tumor stage and malnutrition. However, there is no firm evidence on which variables best...
14.
Banerjee S, Booth C, Bruera E, Buchler M, Drilon A, Fry T, et al.
Nat Rev Clin Oncol
. 2024 Oct;
21(11):771-780.
PMID: 39354161
No abstract available.
15.
Andre T, Van Cutsem E, Taieb J, Fakih M, Prager G, Ciardiello F, et al.
Curr Treat Options Oncol
. 2024 Sep;
25(10):1312-1322.
PMID: 39325367
Recommended first and second line treatments for unresectable metastatic colorectal cancer (mCRC) include fluorouracil-based chemotherapy, anti-vascular endothelial growth factor (VEGF)-based therapy, and anti-epidermal growth factor receptor-targeted therapies. In third line,...
16.
Kopetz S, Murphy D, Pu J, Ciardiello F, Desai J, Van Cutsem E, et al.
Nat Med
. 2024 Sep;
30(11):3261-3271.
PMID: 39313594
The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF-V600E-mutant mCRC, providing the basis for...
17.
Janjigian Y, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges J, et al.
N Engl J Med
. 2024 Sep;
391(14):1360-1362.
PMID: 39282917
No abstract available.
18.
Usset J, Rosendahl Huber A, Andrianova M, Batlle E, Carles J, Cuppen E, et al.
Nat Genet
. 2024 Sep;
56(10):2112-2120.
PMID: 39266764
Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response...
19.
Segal N, Tie J, Kopetz S, Ducreux M, Chen E, Dienstmann R, et al.
Br J Cancer
. 2024 Jul;
131(6):1005-1013.
PMID: 39048638
Background: To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab (anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti-tumour effect in patients with metastatic colorectal cancer (mCRC). Methods:...
20.
Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Gerlinger M, et al.
Future Oncol
. 2024 Jul;
20(24):1733-1743.
PMID: 39041200
Most patients with metastatic colorectal cancer (mCRC) have limited treatment options following standard-of-care therapy. VEGFR-tyrosine kinase inhibitors (TKIs) have demonstrated clinical activity in mCRC in combination with immune checkpoint inhibitors...